Followers | 180 |
Posts | 24737 |
Boards Moderated | 16 |
Alias Born | 04/03/2002 |
Thursday, July 25, 2019 12:48:20 PM
DarioHealth offers USB-C connector configuration between Android smart mobile devices and the Dario Blood Glucose Meter
NEW YORK and CAESAREA, Israel, July 25, 2019 /PRNewswire/ -- Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today announced that its CE certificate covers a USB-C connector enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The USB-C connector is used to transfer power and communication signals between Android smart mobile devices and the Dario meter, and ensures that consumers, beginning with the Europe market region, will receive the same quality user experience with DarioHealth on the latest Android smart phone devices.
https://mma.prnewswire.com/media/837114/DarioHealth_Logo.jpg
Android smart mobile device manufacturers differentiate lines of products across their markets aimed at different user populations, with varying product specifications and product price points. The USB-C connector standard is gradually gaining market share over its main predecessor, the micro-USB, in smart mobile devices. By focusing on high-end Android devices, Dario aims to extend its footprint and have the widest market reach. The Dario Blood Glucose Monitoring System is currently used with the Samsung Galaxy and LG family smart mobile Android devices.
Erez Raphael, Chairman and CEO of DarioHealth, commented, "Dario is always looking to stay ahead of the curve and meet the latest technological developments in the market head on. Current mobile technology is rapidly embracing the USB-C standard and we have been working tirelessly to bring a solution that accommodates this protocol. We are proud that our organization has worked with speed and agility to ensure connectivity to the latest Android devices. This significant milestone will allow us to open a whole new market segment and re-engage with former-Dario users who now have the newest Android devices. This is a big breakthrough for us in the European market as an estimated 60 million people have diabetes in Europe. Now more consumers in Europe can benefit from the Dario digital therapeutics solution through their smartphone."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way.
DarioHealth's cross functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding solutions for additional chronic conditions such as hypertension and moving into new geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that it by focusing on high-end Android devices, it aims to extend its footprint and have the widest market reach, that the approval of USB-C connector is a significant milestone that will allow it to open a whole new market segment and re-engage with former-Dario users who now have the newest Android devices and that more consumers in Europe can benefit from the Dario digital therapeutics solution through their smartphone, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
+1-347-767-4220
https://c212.net/c/img/favicon.png?sn=LN23434&sd=2019-07-25 View original content to download multimedia:http://www.prnewswire.com/news-releases/dariohealth-usb-type-c-connector-for-the-european-android-market-is-ce-marked-300890918.html
SOURCE DarioHealth Corp.
Recent DRIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:02:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:01:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 12:30:15 PM
- Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer • PR Newswire (US) • 06/05/2024 12:30:00 PM
- DarioHealth Reports First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 05/15/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 10:06:09 AM
- DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th • PR Newswire (US) • 05/07/2024 12:30:00 PM
- Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes • PR Newswire (US) • 04/25/2024 12:30:00 PM
- Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health • PR Newswire (US) • 04/02/2024 12:30:00 PM
- DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH • PR Newswire (US) • 03/21/2024 12:30:00 PM
- New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications • PR Newswire (US) • 03/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:24:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:20:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:16:57 PM
- DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE • PR Newswire (US) • 02/28/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:05:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:16:56 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM